Freebies to doctors: Why has the ethical code not been enforced? How has EPFO's equity investment experience been? Are FMCG companies eyeing better margins ahead? What is moonlighting? Answers here
China accounts for about one-fifth of FY22 numbers; 41% surge overall
Centre also proposes to have an expert group on medical devices
During Covid-19, most patients were suffering from high temperatures, and the sales of this brand skyrocketed
A team of more than 20 officers associated with the I-T dept conducted the raids on the pharma company's Race Course Road office
The company has received 99 per cent of votes at the shareholders meeting held on Tuesday, PEL said in a statement
Competitive pressures, high valuations limit upsides for listed lab chains
Pain and fever drug Paracetamol and blood-clot preventing Enoxaparin both post growth rates beyond 20%
Exact stake size not revealed, sources put the number at 70%
The geopolitical incidents of the recent past as well as the pandemic have not really helped cost pressure: Tambe
India has over 750 USFDA approved plants and over 4000 products which are approved by either the US or EU or any other stringent regulator.
Cipla, which has seen a generational change in its leadership, draws 40 per cent of its revenues from India and 21 per cent from the US market.
The funds raised by MedisimVR will be used by the company for scaling up its product offering and adding more skill training content to their library
The agreement further adds to company's portfolio of medicines for rare and orphan diseases
India Ratings and Research (Ind-Ra) said it has maintained a neutral outlook for the Indian pharmaceutical sector for FY23.
US price erosion, India growth trends would be keenly tracked
His remarks assume significance at a time when a large number of Indian students, many of them studying medicine, have been stuck in Ukraine following the Russian attack on that country.
MediBuddy, which recently got actor Amitabh Bachchan as a brand ambassador, is aiming to scale up business
Fitch estimates the pharma company's EBITDA to drop significantly in FY23 due to lower volume and narrowing of the margin to 11%
Efforts to lower prescription drug costs have long been popular with voters, but bipartisan consensus has proved elusive. It's unclear if there's a political path forward for Biden's plans in Congress